DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Quizartinib is an investigational drug.
There have been 32 clinical trials for Quizartinib. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2014.
The most common disease conditions in clinical trials are Leukemia, Leukemia, Myeloid, Acute, and Leukemia, Myeloid. The leading clinical trial sponsors are Daiichi Sankyo, Inc., National Cancer Institute (NCI), and Daiichi Sankyo Co., Ltd.
There are two hundred and eighty-six US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Quizartinib
|Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML||Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company||Phase 3|
|Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML||University Hospital Heidelberg||Phase 3|
|A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects||Daiichi Sankyo, Inc.||Phase 1|
Top disease conditions for Quizartinib
Top clinical trial sponsors for Quizartinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Quizartinib||⤷ Sign up for a Free Trial||Peptides and combination of peptides for use in immunotherapy against various tumors||IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE)||⤷ Sign up for a Free Trial|
|Quizartinib||⤷ Sign up for a Free Trial||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||⤷ Sign up for a Free Trial|
|Quizartinib||⤷ Sign up for a Free Trial||Peptides and combination of peptides for use in immunotherapy against various tumors||IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)||⤷ Sign up for a Free Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Quizartinib||Argentina||AR104113||2035-03-27||⤷ Sign up for a Free Trial|
|Quizartinib||Argentina||AR112781||2035-03-27||⤷ Sign up for a Free Trial|
|Quizartinib||Australia||AU2016239920||2035-03-27||⤷ Sign up for a Free Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|